ArticleOncology letters2025
miR‑106b‑5p in stage II left‑sided and right‑sided colon cancer and its association with the prognostic characteristics of patients.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miR)-106b-5p is highly expressed in colon cancer; however, data on its expression levels in left-sided colon cancer (LCC) vs. right-sided colon cancer (RCC) is lacking. The present study aimed to assess the differences in miR-106b-5p expression in stage II LCC and RCC, as well as its relationship with patient prognosis. From August 2018 to February 2020, 40 specimens of primary stage II colon cancer were collected from Huizhou First Hospital (Huizhou, China), which included 20 cases of LCC and 20 cases of RCC. The miR-106b-5p expression levels in cancer tissues were compared with normal adjacent tissues, as well as between LCC and RCC tissues, and survival outcomes were assessed. miR-106b-5p expression was significantly higher in stage II LCC tissues compared with RCC tissues. However, no significant difference in 5-year survival was observed between the two groups. Notably, 5-year survival was significantly lower in the high miR-106b-5p expression group compared with the low expression group among patients with RCC. By contrast, there were no survival differences between the high and low miR-106b-5p expression groups in LCC. Multivariate analysis indicated that miR-106b-5p expression was an independent prognostic factor for patients with RCC. In conclusion, miR-106b-5p expression was significantly upregulated in colon cancer tissues, with higher expression levels demonstrated in LCC compared with RCC. High miR-106b-5p expression in RCC was identified as an independent prognostic factor, whilst its expression in LCC did not show a significant association with prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.